Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Gross Margin (2023 - 2025)

Fennec Pharmaceuticals' Gross Margin history spans 3 years, with the latest figure at 55.68% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 545.0% year-over-year to 55.68%, compared with a TTM value of 71.65% through Dec 2025, down 621.0%, and an annual FY2025 reading of 58.3%, down 294.0% over the prior year.
  • Gross Margin for Q4 2025 was 55.68% at Fennec Pharmaceuticals, down from 58.19% in the prior quarter.
  • The five-year high for Gross Margin was 97.83% in Q1 2024, with the low at 35.67% in Q2 2024.
  • Average Gross Margin over 3 years is 78.47%, with a median of 91.47% recorded in 2023.
  • Year-over-year, Gross Margin plummeted -5988bps in 2024 and then surged 5432bps in 2025.
  • Tracing FENC's Gross Margin over 3 years: stood at 92.96% in 2023, then crashed by -46bps to 50.23% in 2024, then rose by 11bps to 55.68% in 2025.
  • Per Business Quant, the three most recent readings for FENC's Gross Margin are 55.68% (Q4 2025), 58.19% (Q3 2025), and 89.98% (Q2 2025).